Cargando…

Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study

BACKGROUND AND PURPOSE: Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM). We hypothesised that obese women requiring differing treatment modalities for GDM may have diverse underlying metabolic pathways. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Sara L., Begum, Shahina, Vieira, Matias C., Seed, Paul, Lawlor, Deborah L., Sattar, Naveed, Nelson, Scott M., Welsh, Paul, Pasupathy, Dharmintra, Poston, Lucilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117764/
https://www.ncbi.nlm.nih.gov/pubmed/32240196
http://dx.doi.org/10.1371/journal.pone.0230658
_version_ 1783514439448788992
author White, Sara L.
Begum, Shahina
Vieira, Matias C.
Seed, Paul
Lawlor, Deborah L.
Sattar, Naveed
Nelson, Scott M.
Welsh, Paul
Pasupathy, Dharmintra
Poston, Lucilla
author_facet White, Sara L.
Begum, Shahina
Vieira, Matias C.
Seed, Paul
Lawlor, Deborah L.
Sattar, Naveed
Nelson, Scott M.
Welsh, Paul
Pasupathy, Dharmintra
Poston, Lucilla
author_sort White, Sara L.
collection PubMed
description BACKGROUND AND PURPOSE: Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM). We hypothesised that obese women requiring differing treatment modalities for GDM may have diverse underlying metabolic pathways. METHODS: In this secondary analysis of the UK pregnancies Better Eating and Activity Trial (UPBEAT) we studied women from the control arm with complete biochemical data at three gestational time points; at 15–18(+6) and 27–28(+6) weeks (before treatment), and 34–36(+0) weeks (after treatment). A total of 89 analytes were measured (plasma/serum) using a targeted nuclear magnetic resonance (NMR) platform and conventional assays. We used linear regression with appropriate adjustment to model metabolite concentration, stratified by treatment group. MAIN FINDINGS: 300 women (median BMI 35kg/m(2); inter quartile range 32.8–38.2) were studied. 71 developed GDM; 28 received dietary treatment only, 20 metformin, and 23 received insulin. Prior to the initiation of treatment, multiple metabolites differed (p<0.05) between the diet and insulin-treated groups, especially very large density lipoprotein (VLDL) and high density lipoprotein (HDL) subclasses and constituents, with some differences maintained at 34–36 weeks’ gestation despite treatment. Gestational lipid profiles of the diet treatment group were indicative of a lower insulin resistance profile, when compared to both insulin-treated women and those without GDM. At 28 weeks’ the diet treatment group had lower plasma fasting glucose and insulin than women treated with insulin, yet similar to those without GDM, consistent with a glycaemic mechanism independent of insulin resistance. CONCLUSIONS/INTERPRETATION: This exploratory study suggests that GDM pathophysiological processes may differ amongst obese women who require different treatment modalities to achieve glucose control and can be revealed using metabolic profiling.
format Online
Article
Text
id pubmed-7117764
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-71177642020-04-09 Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study White, Sara L. Begum, Shahina Vieira, Matias C. Seed, Paul Lawlor, Deborah L. Sattar, Naveed Nelson, Scott M. Welsh, Paul Pasupathy, Dharmintra Poston, Lucilla PLoS One Research Article BACKGROUND AND PURPOSE: Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM). We hypothesised that obese women requiring differing treatment modalities for GDM may have diverse underlying metabolic pathways. METHODS: In this secondary analysis of the UK pregnancies Better Eating and Activity Trial (UPBEAT) we studied women from the control arm with complete biochemical data at three gestational time points; at 15–18(+6) and 27–28(+6) weeks (before treatment), and 34–36(+0) weeks (after treatment). A total of 89 analytes were measured (plasma/serum) using a targeted nuclear magnetic resonance (NMR) platform and conventional assays. We used linear regression with appropriate adjustment to model metabolite concentration, stratified by treatment group. MAIN FINDINGS: 300 women (median BMI 35kg/m(2); inter quartile range 32.8–38.2) were studied. 71 developed GDM; 28 received dietary treatment only, 20 metformin, and 23 received insulin. Prior to the initiation of treatment, multiple metabolites differed (p<0.05) between the diet and insulin-treated groups, especially very large density lipoprotein (VLDL) and high density lipoprotein (HDL) subclasses and constituents, with some differences maintained at 34–36 weeks’ gestation despite treatment. Gestational lipid profiles of the diet treatment group were indicative of a lower insulin resistance profile, when compared to both insulin-treated women and those without GDM. At 28 weeks’ the diet treatment group had lower plasma fasting glucose and insulin than women treated with insulin, yet similar to those without GDM, consistent with a glycaemic mechanism independent of insulin resistance. CONCLUSIONS/INTERPRETATION: This exploratory study suggests that GDM pathophysiological processes may differ amongst obese women who require different treatment modalities to achieve glucose control and can be revealed using metabolic profiling. Public Library of Science 2020-04-02 /pmc/articles/PMC7117764/ /pubmed/32240196 http://dx.doi.org/10.1371/journal.pone.0230658 Text en © 2020 White et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
White, Sara L.
Begum, Shahina
Vieira, Matias C.
Seed, Paul
Lawlor, Deborah L.
Sattar, Naveed
Nelson, Scott M.
Welsh, Paul
Pasupathy, Dharmintra
Poston, Lucilla
Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study
title Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study
title_full Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study
title_fullStr Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study
title_full_unstemmed Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study
title_short Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study
title_sort metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: an exploratory study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117764/
https://www.ncbi.nlm.nih.gov/pubmed/32240196
http://dx.doi.org/10.1371/journal.pone.0230658
work_keys_str_mv AT whitesaral metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT begumshahina metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT vieiramatiasc metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT seedpaul metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT lawlordeborahl metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT sattarnaveed metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT nelsonscottm metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT welshpaul metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT pasupathydharmintra metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT postonlucilla metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy
AT metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy